Adjuvant radiotherapy in stage Ⅰ-Ⅱ epithelial ovarian cancer

Objective: The purpose of this study was to assess the efficacy and side-effects of abdominopelvic irradiation applied as adjuvant postoperative therapy in early stage ovarian carcinomas.

Methods: From 1 January 1988 to 31 December 1993, 113 patients with FIGO stage IA-IIC epithelial ovarian carcinoma were treated with postoperative radiotherapy. Whole abdominal irradiation or lower abdominopelvic irradiation was used. The dose of specification was 20 Gy to the upper part of the abdominal cavity and 40 Gy to the lower part of the abdomen and the pelvic region.

Results: Primary cure was achieved in 110 patients (97%). During the period of follow-up, 33 cases of tumor recurrences (30%) were recorded. Abdominopelvic metastases were most frequent (18%). The overall 5-year survival rate for the complete series was 69% and the cancer-specific survival rate was 72%. Tumor grade was an independent and significant prognostic factor (Cox multivariate analysis; p = 0.007). Early radiation reactions of any type were noted in 93% of the cases and, in 11%, discontinuation of radiotherapy was necessary. Late radiation reactions were noted in 58% of the cases and the most common side-effect was diarrhea, but in most cases these reactions were of limited clinical significance. The incidence of severe bowel toxicity was 10% and, in two patients ( 1.8%), surgery was necessary due to late radiation reactions.

Conclusions: Adjuvant abdominopelvic radiotherapy is one option among others (e.g. various types of chemotherapy or no further treatment) in primary treatment of early stage ovarian carcinoma. The optimal adjuvant therapy for this group of patients is not known today and further prospective and randomized studies are needed.

Ovarian cancer; Early stages; Adjuvant therapy; Radiotherapy; Prognosis

[1] Benjamin I., Rubin S. C.: "Management of early-stage epithelial ovarian cancer". Obstet. Gynecol. Clin. North Am., 1994, 21, 107.

[2] Macbeth F. R., MacDonald H., Williams C. J.: "Total abdominal and pelvic radiotherapy in the management of early stage ovarian carcinoma". Int. J. Radial. Oneal. Biol. Phys., 1988, 15, 353.

[3] Soper J. T.: "Management of early-stage epithelial ovarian cancer". Clin. Obstet. Gynecol., 1994, 37, 423.

[4] De Rijke J. M., Schouten L. J., Volovics A., van der Putten H.W.H.M.: "Age-specific differences in treatment and survival of ovarian cancer patients in the province of Limburg, the Netherlands 1986-92". Int. J. Gynecol. Cancer, 1998, 8, 150.

[5] Diebold J.: "Molekulargenetik der epithelialen Ovarialneoplasien Korrelationen zum Phiinotyp und biologischen Verhalten". Pathologie, 1998, 19, 95.

[6] Gadducci A., Sartori E., Maggino T., Zola P., Landoni F., Fanucchi A. et al.: "Analysis of failures in patients with stage I ovarian cancer: An Italian multicenter study". Int. J. Gynecol. Cancer, 1997, 8, 445.

[7] Schueler J. A., Trimbos J. B., Hermans J., Fleuren G. J.: "The yield of surgical staging in presumed early stage ovarian cancer Benefits or doubts?". Int. J. Gynecol. Cancer, 1998, 8, 95.

[8] Cannistra S. A.: "Cancer of the ovary". N. Engl. J. Med.,1993, 239, 1550.

[9] Baiocchi G.,R aspagliesi F.,G rosso G.,F ontanelli R.,C obellis L., di Re E.,di Re F.: "Early ovarian cancer: Is there a role for systematic pelvic and para-aortic lymphadenectomy?". Int. J. Gynecol Cancer, 1998, 8, 103.

[10] Souchon M., Cwiekala M.: "Postoperative Therapie des epithehaJen Ovarialkarzinoms". Strahlenther. Onkol., 1995, 171, 630.

[11] Lax S. F., Petru E., Holzer E., Pert! A. M., Ralph G., Greenspan D. L. et al.: "Mesenteric and mesocolic lymph node metastases from ovarian carcinoma: A clinicopathological analysis". Int. J. Gynecol. Cancer,1998, 8, 119.

[12] Fyles A., Bolis G., F erraris C., Bolla M., Parazzini F.: "Current controversies in cancer: Is abdomino-pelvic radiation therapy the optimal treatment for completely resected stage I and II high risk ovarian cancer?". Eur. J. Cancer, 1997, 33, 12.

[13] Sorbe B., Nordqvist S.: "Adjuvant radiotherapy in early stage ovarian carcinoma". Int. J. Oncol., 1997, 10, 945.

[14] Sartori E., Palai N., La F ace B., Pecorelli S., Bianchi U.A .: "Epithelial ovarian cancer: An open question". Eur. J. Gynecol Oncol., 1994, 15, 188.

[15] Reinfuss M., Kojs Z., Skolyszewski J.:''External beam radiotherapy in the management of ovarian carcinoma". Radiother. Oneal., 1993, 26, 26.

[16] Pecorelli S., Odicino F., Maisonneuve P.: "Carcinoma of the ovary". J. Epidemiol. Biostat., 1998, 3(1), 75.

[17] Morton G. C., Thomas G. M.: "Is there a place for whole abdominal radiotherapy in the management of ovarian cancer?". Ann. Acad. Med., 1996, 25, 429.

[18] Dembo A. J.: "Abdominopelvic radiotherapy in ovarian cancer (A 10-year experience)". Cancer, 1985, 55, 2285.

[19] Dembo A. J., Bush R. S., Beale H. A., Pringle J. F., Stugeon J. F.G.: "The Princess Margaret Hospital study of ovarian cancer: Stages I, II and asymptomatic III presentations". Int. J. Radial. Oncol. Biol. Phys., 1979, 63, 249.

[20] Leers W. H., Kock H. C. L. V.: "The evaluation of postoperative irradiation in patients with early-stage ovarian cancer". Gynecol. Oncol., 1987, 28, 41.

[21] Dembo A. J.: "Epithelial ovarian cancer: The role of radiotherapy". Int. J. Radial. Oncol. Biol. Phys., 1992, 22, 835.

[22] Sell A., Bertelsen K., Andersen J. E., Stri:iyer I., Panduro J.: "Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer". Gynecol. Oncol., 1990, 37, 367.

[23] Dembo A. J., Pringle J. F.: "Radiotherapy in ovarian cancer. Mu]timodal treatment of ovarian cancer" edited by Conte P. F. et al. Raven Press, New York, 1989, 181.

[24] Ahmed F. Y., Wiltshaw E., A'Hern R. P., Nicol B., Shepherd J., Blake P. et al.: "Natural history and prognosis of untreated stage I epithelial ovarian carcinoma". J. Clin. Oncol., 1996, 14, 2968.

[25] Dembo A. J., Davy M., Stenwig A. E., Berle E. J., Bush R. S., Kjorstad K.: "Prognostic factors in patients with stage I epithelial ovarian cancer". Obstet. Gynecol., 1990, 75, 263.

[26] Levsque M. A., Katsaros D., Yu H., Zola P., Sismondi P., Dia mandis E. P.:" Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma". Cancer, 1995, 6(75), 1327.

[27] Zanella G., Rota S., Chiari S., Bonazzi C., Bratina G., Torri V. et al.: "The accuracy of staging: An important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis". Ann Oncol., 1998, 9, 1097.

[28] Diebold J., Suchy B., Baretton G. B., Blasenbreu S., Schmidt W M. M., Rabes H. et al.: "DNA ploidy and MYC DNA amplification in ovarian carcinomas". Virchows Arch., 1996, 429, 221.

[29] Withers H. R., Peters L. J., Taylor J. M. G.: "Dose-response relatioship for radiation therapy of subclinicaJ disease". Int. J. Radial Oncol. Biol. Phys., 1994, 31, 353.

[30] Colombo N., Chiari S., Maggioni A., Bocciolone L., Torri Y., Mangioni C.: "Controversial issue、in the management of early epithelial ovarian cancer: Conservative surgery and role of adjuvant therapy". Gynecol. Oncol., 1994, 55, 47.

[31] Soper J. T., Berchuck A., Dodge R., Clarke-Pearson D. L.: "Adjuvant therapy with intraperitoneal chromic phosphate ("P) in women with early ovarian carcinoma after comprehensive surgical staging". Obstet. Gynecol., 1992, 79, 993.

[32] Vergote I. B., Vergote-De Vos L. N., Abeler V. M., Aas M., Lmdegaard M. W., Kjiirstad K. E. et. al.: "Randomized trial comparing cisplatin with radioactive phosphorous or whole-abdomen irradiation as adjuvant treatment of ovarian cancer". Cancer, 1992, 69, 741.

[33] Peters W. A.,S mith M. R.,C ain J.M.,L ee R. B.,Y on J. L.: "Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary". Gynecol. On col., 1992, 47, 146.

[34] MaJmstriim H., Simonsen E., Westberg R.: "A phase II study of intraperitoneal carboplatin as adjuvant treatment in early stage ovarian cancer patients". Gynecol. Oncol., 1992, 52, 20.

[35] Colombo N., Maggioni A., Bocciolone L., Rota S., Cantu M. G., Mangioni C.: "Multimodal therapy of early-stage (F IGO I-II) ovarian cancer: Review of surgical management and postoperative adjuvant treatment". Int. J. Gynecol. Cancer, 1996, 6, 13.

[36] Young R. C., Walton L. A., Ellenberg S. S.: "Adjuvant therapy in stage land II epithelial ovarian cancer. Results of two prospective randomized trials". N. Engl. J. Med., 1990, 322, 1021.

[37] Dembo A. J., Bush R. S., Beale F. A., Bean H. A., Pringle J. F., Sturgeon J., Reid G. J.: "Ovarian carcinoma: Improved survival following abdominopelvic irradiation in patients with a completed pelvic operation". Am. J. Obstet. Gynecol., 1979, 134, 793.